NCT01587989View on ClinicalTrials.gov

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

methotrexate

15-25 mg orally weekly, Weeks 1-12

DRUG

methotrexate

15-25 mg orally weekly, Weeks 13-24

DRUG

placebo

methotrexate placebo orally weekly, Weeks 13-24

DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg iv every 4 weeks, 24 weeks

Trial Locations (13)

1090

Vienna

1100

Vienna

1130

Vienna

1140

Vienna

1160

Vienna

2000

Stockerau

2020

Hollabrunn

4020

Linz

4600

Wels

5020

Salzburg

6020

Innsbruck

8020

Graz-Eggenberg

8036

Graz

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01587989 - A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter